secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001193125-23-191942
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics raises $30M equity, cuts 25% workforce, targets profitability late 2024
--------------------------------------------------------------------------------

- Private placement of 20.7M shares at $1.37 and pre-funded warrants for up to 1.16M shares; gross proceeds ~$30M.
- Cost reduction plan: $75M cash savings through 2025 including $45M operational savings; 25% employee reduction; $5.9M charge in 2023.
- COO David Szekeres resigned July 20, 2023 by mutual agreement; entitled to severance under amended employment agreement.
- Company states financing may be last equity raise before reaching cash flow positivity; aims for profitability late 2024.
- Waiver granted to Rubric and Velan under Cooperation Agreement allowing beneficial ownership above 15%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/0001193125-23-191942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312523191942/d527822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-191942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer